HomeCompareRSVIX vs ABBV

RSVIX vs ABBV: Dividend Comparison 2026

RSVIX yields 99.99% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSVIX wins by $3.79M in total portfolio value
10 years
RSVIX
RSVIX
● Live price
99.99%
Share price
$15.25
Annual div
$15.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.89M
Annual income
$1,312,577.91
Full RSVIX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RSVIX vs ABBV

📍 RSVIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSVIXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSVIX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSVIX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSVIX
Annual income on $10K today (after 15% tax)
$8,499.50/yr
After 10yr DRIP, annual income (after tax)
$1,115,691.22/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RSVIX beats the other by $1,094,635.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSVIX + ABBV for your $10,000?

RSVIX: 50%ABBV: 50%
100% ABBV50/50100% RSVIX
Portfolio after 10yr
$2.00M
Annual income
$668,674.84/yr
Blended yield
33.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RSVIX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSVIX buys
0
ABBV buys
0
No recent congressional trades found for RSVIX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSVIXABBV
Forward yield99.99%3.06%
Annual dividend / share$15.25$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3.89M$102.3K
Annual income after 10y$1,312,577.91$24,771.77
Total dividends collected$3.48M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RSVIX vs ABBV ($10,000, DRIP)

YearRSVIX PortfolioRSVIX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,699$9,999.41$11,550$430.00+$9.1KRSVIX
2$41,492$19,344.10$13,472$627.96+$28.0KRSVIX
3$80,636$36,238.99$15,906$926.08+$64.7KRSVIX
4$152,100$65,819.06$19,071$1,382.55+$133.0KRSVIX
5$278,776$116,029.14$23,302$2,095.81+$255.5KRSVIX
6$497,041$198,751.43$29,150$3,237.93+$467.9KRSVIX
7$863,014$331,180.08$37,536$5,121.41+$825.5KRSVIX
8$1,460,836$537,410.21$50,079$8,338.38+$1.41MRSVIX
9$2,413,263$850,169.39$69,753$14,065.80+$2.34MRSVIX
10$3,894,770$1,312,577.91$102,337$24,771.77+$3.79MRSVIX

RSVIX vs ABBV: Complete Analysis 2026

RSVIXStock

The fund normally invests at least 80% of its assets in common stocks of small companies that are considered to be undervalued in relation to earnings, dividends and/or assets. The Russell 2000® Value Index is an unmanaged index of common stock prices that measures the performance of those Russell 2,000 companies with lower price-to-book ratios and lower forecasted growth values.

Full RSVIX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RSVIX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSVIX vs SCHDRSVIX vs JEPIRSVIX vs ORSVIX vs KORSVIX vs MAINRSVIX vs JNJRSVIX vs MRKRSVIX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.